A new Chinese weight-loss injection, ribupatide, is reported to have produced substantial weight loss in a clinical trial. UK trials are also described as underway, while participants at Shanghai’s Fudan University are said to have lost close to a fifth of their body weight over 11 months.
Outlets frame the news differently around potential impact. The Mirror presents ribupatide as a possible rival to established weight-loss drugs such as Wegovy and Mounjaro, linking this to trial results. Mail Online and the Daily Mail both emphasise comparative effectiveness, highlighting an average weight-loss figure reported for the study. Across the coverage, the common focus is ribupatide’s once-weekly injection schedule and the magnitude of weight change observed so far, with results tied to the ongoing nature of trials rather than confirmed widespread use.